Wall Street Analysts Chiming In on Global Blood Therapeutics, Inc. (NASDAQ:GBT) Giving it a 11
Global Blood Therapeutics, Inc. (NASDAQ:GBT) currently has an Average Broker Rating of 1.27. This number is based on the 15 sell-side firms polled by Zacks. The ABR rank within the industry stands at 11.
Analysts on a consensus basis are expecting that the stock will reach $98.46 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry ...